Duke Energy Corp vs Mesoblast Limited — how do they compare? Duke Energy Corp trades at $116.16 (market cap $91.10B), while Mesoblast Limited trades at $14.13 (market cap $1.75B). The key difference: Duke Energy Corp is far larger — about 52.1× Mesoblast Limited's market cap, and Duke Energy Corp pays a 3.71% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Duke Energy Corp for 74 Days and Mesoblast Limited for 14 Days on average.
| DUK | MESO | |
|---|---|---|
Market Cap | $91.10B | $1.75B |
Volume | 4,199,050 | 239,027 |
Sector | Utilities | Health |
52-Week High | $133.46 | $20.96 |
52-Week Low | $113.23 | $13.19 |
Typical Hold Time | 74 Days | 14 Days |
Enterprise Value | $183.61B | $1.83B |
Dividend Yield | 3.71% | — |
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $115.50, down 0.14% with a bearish technical signal. The company demonstrates strong fundamentals with consistent earnings beats, 15.78% net income margin, and stable dividend payments. Recent news highlights Duke's positioning in data center growth opportunities while facing pressure from rising Treasury yields. The stock trades below analyst consensus target of $134.44 with 43.75% buy ratings.
DUK offers income investors a stable utility play with growth potential from data center demand, though rising interest rates and high debt levels present headwinds. The current valuation at 17.6 P/E appears reasonable given the company's consistent profitability and dividend reliability. Upside potential exists if data center contracts materialize as projected.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Trailing returns across standard periods
Latest headlines on both assets
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →